Primary sclerosing cholangitis

Clinics in Liver Disease

Volumn 8, Issue 1, 2004, Pages 195-211

  Mendes, Flavia D ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AZATHIOPRINE; BILE ACID; BUDESONIDE; CLADRIBINE; COLCHICINE; CORTICOSTEROID; ENDOTOXIN; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; NALTREXONE; NICOTINE; ONDANSETRON; PENICILLAMINE; PENTOXIFYLLINE; PIRFENIDONE; PLACEBO; PREDNISOLONE; PREDNISONE; RIFAMPICIN; TACROLIMUS; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; BACTERIUM; BILE DUCT CARCINOMA; BILE DUCT INJURY; CANCER DIAGNOSIS; CANCER RISK; CHOLANGIOGRAPHY; CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; EARLY DIAGNOSIS; ENDOSCOPY; FATIGUE; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HISTORY; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; ISCHEMIA; JAUNDICE; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MORBIDITY; MORTALITY; OSTEOLYSIS; PATHOGENESIS; PILOT STUDY; PORTAL HYPERTENSION; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; PRURITUS; REVIEW; SIDE EFFECT; STAGING; SURGICAL TECHNIQUE; SYMPTOM; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNITED STATES;

CHOLANGITIS, SCLEROSING; HUMANS; PROGNOSIS;

EID: 1642335582     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00127-2     Document Type: Review

References (96)

1. Boberg K.M., Aadland E., Jahnsen J., Raknerud N., Stiris M., Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 33(1):1998;99-103.
2. Escorsell A., Pares A., Rodes J., Solis-Herruzo J.A., Miras M., de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol. 21(5):1994;787-791.
3. Olsson R., Danielsson A., Jarnerot G., Lindstrom E., Loof L., Rolny P.et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 100(5 Pt 1):1991;1319-1323.
4. Schrumpf E., Elgjo K., Fausa O., Gjone E., Kolmannskog F., Ritland S. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol. 15(6):1980;689-697.
5. Shepherd H.A., Selby W.S., Chapman R.W., Nolan D., Barbatis C., McGee J.O.et al. Ulcerative colitis and persistent liver dysfunction. Q J Med. 52(208):1983;503-513.
6. van Erpecum K.J., Smits S.J., van de Meeberg P.C., Linn F.H., Wolfhagen F.H., vanBerge-Henegouwen G.P.et al. Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. Gastroenterology. 110(5):1996;1503-1506.
7. Loftus E.V. Jr., Sandborn W.J., Tremaine W.J., Mahoney D.W., Zinsmeister A.R., Offord K.P.et al. Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology. 110(5):1996;1496-1502.
8. Mitchell S.A., Thyssen M., Orchard T.R., Jewell D.P., Fleming K.A., Chapman R.W. Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut. 51(4):2002;567-573.
9. Broome U., Olsson R., Loof L., Bodemar G., Hultcrantz R., Danielsson A. et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 38(4):1996;610-615.
10. Farrant J.M., Hayllar K.M., Wilkinson M.L., Karani J., Portmann B.C., Westaby D.et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology. 100(6):1991;1710-1717.
11. Wiesner R.H., Grambsch P.M., Dickson E.R., Ludwig J., MacCarty R.L., Hunter E.B.et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology. 10(4):1989;430-436.
12. Dickson E.R., Murtaugh P.A., Wiesner R.H., Grambsch P.M., Fleming T.R., Ludwig J.et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology. 103(6):1992;1893-1901.
13. Kim W.R., Therneau T.M., Wiesner R.H., Poterucha J.J., Benson J.T., Malinchoc M.et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 75(7):2000;688-694.
14. Quigley E.M., LaRusso N.F., Ludwig J., MacSween R.N., Birnie G.G., Watkinson G. Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 85(5):1983;1160-1165.
15. Chapman R.W., Varghese Z., Gaul R., Patel G., Kokinon N., Sherlock S. Association of primary sclerosing cholangitis with HLA-B8. Gut. 24(1):1983;38-41.
16. Farrant J.M., Doherty D.G., Donaldson P.T., Vaughan R.W., Hayllar K.M., Welsh K.I.et al. Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology. 16(2):1992;390-395.
17. Schrumpf E., Fausa O., Forre O., Dobloug J.H., Ritland S., Thorsby E. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol. 17(2):1982;187-191.
18. Olerup O., Olsson R., Hultcrantz R., Broome U. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology. 108(3):1995;870-878.
19. Donaldson P.T., Farrant J.M., Wilkinson M.L., Hayllar K., Portmann B.C., Williams R. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology. 13(1):1991;129-133.
20. Mehal W.Z., Lo Y.M., Wordsworth B.P., Neuberger J.M., Hubscher S.C., Fleming K.A.et al. HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis. Gastroenterology. 106(1):1994;160-167.
21. Bernal W., Moloney M., Underhill J., Donaldson P.T. Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis. J Hepatol. 30(2):1999;237-241.
22. Saarinen S., Olerup O., Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol. 95(11):2000;3195-3199.
23. Bodenheimer H.C. Jr., LaRusso N.F., Thayer W.R. Jr., Charland C., Staples P.J., Ludwig J. Elevated circulating immune complexes in primary sclerosing cholangitis. Hepatology. 3(2):1983;150-154.
24. Senaldi G., Donaldson P.T., Magrin S., Farrant J.M., Alexander G.J., Vergani D.et al. Activation of the complement system in primary sclerosing cholangitis. Gastroenterology. 97(6):1989;1430-1434.
25. Angulo P., Peter J.B., Gershwin M.E., DeSotel C.K., Shoenfeld Y., Ahmed A.E.et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol. 32(2):2000;182-187.
26. Lo S.K., Fleming K.A., Chapman R.W. Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique. Gut. 33(10):1992;1370-1375.
27. Bansi D., Chapman R., Fleming K. Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass. J Hepatol. 24(5):1996;581-586.
28. Roozendaal C., Van Milligen de Wit A.W., Haagsma E.B., Horst G., Schwarze C., Peter H.H.et al. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am J Med. 105(5):1998;393-399.
29. Mandal A., Dasgupta A., Jeffers L., Squillante L., Hyder S., Reddy R.et al. Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium. Gastroenterology. 106(1):1994;185-192.
30. Xu B., Broome U., Ericzon B.G., Sumitran-Holgersson S. High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut. 51(1):2002;120-127.
31. Lee Y.M., Kaplan M.M. Primary sclerosing cholangitis. N Engl J Med. 332(14):1995;924-933.
32. Sasatomi K., Noguchi K., Sakisaka S., Sata M., Tanikawa K. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 29(3):1998;409-416.
33. Olsson R., Bjornsson E., Backman L., Friman S., Hockerstedt K., Kaijser B.et al. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol. 28(3):1998;426-432.
34. Ponsioen C.Y., Vrouenraets S.M., Prawirodirdjo W., Rajaram R., Rauws E.A., Mulder C.J.et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut. 51(4):2002;562-566.
35. Kaw M., Silverman W.B., Rabinovitz M., Schade R.R. Biliary tract calculi in primary sclerosing cholangitis. Am J Gastroenterol. 90(1):1995;72-75.
36. Hay J.E., Lindor K.D., Wiesner R.H., Dickson E.R., Krom R.A., LaRusso N.F. The metabolic bone disease of primary sclerosing cholangitis. Hepatology. 14(2):1991;257-261.
37. Angulo P., Therneau T.M., Jorgensen A., DeSotel C.K., Egan K.S., Dickson E.R.et al. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol. 29(5):1998;729-735.
38. Bergquist A., Ekbom A., Olsson R., Kornfeldt D., Loof L., Danielsson A. et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 36(3):2002;321-327.
39. Chalasani N., Baluyut A., Ismail A., Zaman A., Sood G., Ghalib R.et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology. 31(1):2000;7-11.
40. Bergquist A., Glaumann H., Persson B., Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology. 27(2):1998;311-316.
41. Harnois D.M., Gores G.J., Ludwig J., Steers J.L., LaRusso N.F., Wiesner R.H. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol. 27(3):1997;512-516.
42. Brentnall T.A., Haggitt R.C., Rabinovitch P.S., Kimmey M.B., Bronner M.P., Levine D.S.et al. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 110(2):1996;331-338.
43. Kornfeld D., Ekbom A., Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut. 41(4):1997;522-525.
44. Lindberg B.U., Broome U., Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum. 44(1):2001;77-85.
45. Shetty K., Rybicki L., Brzezinski A., Carey W.D., Lashner B.A. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 94(6):1999;1643-1649.
46. Angulo P., Pearce D.H., Johnson C.D., Henry J.J., LaRusso N.F., Petersen B.T.et al. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol. 33(4):2000;520-527.
47. Fulcher A.S., Turner M.A., Franklin K.J., Shiffman M.L., Sterling R.K., Luketic V.A.et al. Primary sclerosing cholangitis: evaluation with MR cholangiography-a case-control study. Radiology. 215(1):2000;71-80.
48. Vitellas K.M., El-Dieb A., Vaswani K.K., Bennett W.F., Tzalonikou M., Mabee C.et al. MR cholangiopancreatography in patients with primary sclerosing cholangitis: interobserver variability and comparison with endoscopic retrograde cholangiopancreatography. AJR Am J Roentgenol. 179(2):2002;399-407.
49. Vitellas K.M., Enns R.A., Keogan M.T., Freed K.S., Spritzer C.E., Baillie J.et al. Comparison of MR cholangiopancreatographic techniques with contrast-enhanced cholangiography in the evaluation of sclerosing cholangitis. AJR Am J Roentgenol. 178(2):2002;327-334.
50. Angulo P., Larson D.R., Therneau T.M., LaRusso N.F., Batts K.P., Lindor K.D. Time course of histological progression in primary sclerosing cholangitis. Am J Gastroenterol. 94(11):1999;3310-3313.
51. Chazouilleres O., Poupon R., Capron J.P., Metman E.H., Dhumeaux D., Amouretti M.et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol. 11(1):1990;120-123.
52. O'Brien C.B., Senior J.R., Arora-Mirchandani R., Batta A.K., Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology. 14(5):1991;838-847.
53. Beuers U., Spengler U., Kruis W., Aydemir U., Wiebecke B., Heldwein W.et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. 16(3):1992;707-714.
54. Lindor K.D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med. 336(10):1997;691-695.
55. Harnois D.M., Angulo P., Jorgensen R.A., Larusso N.F., Lindor K.D. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol. 96(5):2001;1558-1562.
56. Mitchell S.A., Bansi D.S., Hunt N., Von Bergmann K., Fleming K.A., Chapman R.W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology. 121(4):2001;900-907.
57. Tung B.Y., Emond M.J., Haggitt R.C., Bronner M.P., Kimmey M.B., Kowdley K.V.et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 134(2):2001;89-95.
58. Pardi D.S., Loftus E.V. Jr., Kremers W.K., Keach J., Lindor K.D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 124(4):2003;889-893.
59. Knox T.A., Kaplan M.M. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology. 106(2):1994;494-499.
60. Van Thiel D.H., Carroll P., Abu-Elmagd K., Rodriguez-Rilo H., Irish W., McMichael J.et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol. 90(3):1995;455-459.
61. Duchini A., Younossi Z.M., Saven A., Bordin G.M., Knowles H.J., Pockros P.J. An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol. 31(4):2000;292-296.
62. Bharucha A.E., Jorgensen R., Lichtman S.N., LaRusso N.F., Lindor K.D. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 95(9):2000;2338-2342.
63. Angulo P., Batts K.P., Jorgensen R.A., LaRusso N.A., Lindor K.D. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 95(9):2000;2333-2337.
64. Olsson R., Broome U., Danielsson A., Hagerstrand I., Jarnerot G., Loof L.et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology. 108(4):1995;1199-1203.
65. LaRusso N.F., Wiesner R.H., Ludwig J., MacCarty R.L., Beaver S.J., Zinsmeister A.R. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology. 95(4):1988;1036-1042.
66. Angulo P., MacCarty R.L., Sylvestre P.B., Jorgensen R.A., Wiesner R.H., LaRusso N.A.et al. Pirfenidone in the treatment of primary sclerosing cholangitis. Dig Dis Sci. 47(1):2002;157-161.
67. Vleggaar F.P., van Buuren H.R., van Berge Henegouwen G.P., Hop W.C., van Erpecum K.J. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. Eur J Gastroenterol Hepatol. 13(2):2001;171-175.
68. Angulo P., Bharucha A.E., Jorgensen R.A., DeSotel C.K., Sandborn W.J., Larusso N.F.et al. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci. 44(3):1999;602-607.
69. Lindor K.D., Wiesner R.H., Colwell L.J., Steiner B., Beaver S., LaRusso N.F. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol. 86(1):1991;57-61.
70. Lindor K.D., Jorgensen R.A., Anderson M.L., Gores G.J., Hofmann A.F., LaRusso N.F. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol. 91(3):1996;511-515.
71. Schramm C., Schirmacher P., Helmreich-Becker I., Gerken G., zum Buschenfelde K.H., Lohse A.W. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med. 131(12):1999;943-946.
72. van Hoogstraten H.J., Vleggaar F.P., Boland G.J., van Steenbergen W., Griffioen P., Hop W.C.et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol. 95(8):2000;2015-2022.
73. Stiehl A., Rudolph G., Sauer P., Benz C., Stremmel W., Walker S.et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol. 26(3):1997;560-566.
74. Allison M.C., Burroughs A.K., Noone P., Summerfield J.A. Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical, cholangiographic and bacteriological study. J Hepatol. 3(1):1986;118-122.
75. Ponsioen C.Y., Lam K., van Milligen de Wit A.W., Huibregtse K., Tytgat G.N. Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol. 94(9):1999;2403-2407.
76. van Milligen de Wit A.W., van Bracht J., Rauws E.A., Jones E.A., Tytgat G.N., Huibregtse K. Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc. 44(3):1996;293-299.
77. van Milligen de Wit A.W., Rauws E.A., van Bracht J., Mulder C.J., Jones E.A., Tytgat G.N.et al. Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc. 46(4):1997;344-347.
78. Wagner S., Gebel M., Meier P., Trautwein C., Bleck J., Nashan B.et al. Endoscopic management of biliary tract strictures in primary sclerosing cholangitis. Endoscopy. 28(7):1996;546-551.
79. Lee J.G., Schutz S.M., England R.E., Leung J.W., Cotton P.B. Endoscopic therapy of sclerosing cholangitis. Hepatology. 21(3):1995;661-667.
80. Kaya M., Petersen B.T., Angulo P., Baron T.H., Andrews J.C., Gostout C.J.et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol. 96(4):2001;1059-1066.
81. Stiehl A., Rudolph G., Kloters-Plachky P., Sauer P., Walker S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol. 36(2):2002;151-156.
82. Baluyut A.R., Sherman S., Lehman G.A., Hoen H., Chalasani N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc. 53(3):2001;308-312.
83. Ahrendt S.A., Pitt H.A., Kalloo A.N., Venbrux A.C., Klein A.S., Herlong H.F.et al. Primary sclerosing cholangitis: resect, dilate, or transplant? Ann Surg. 227(3):1998;412-423.
84. Hay J.E. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection? Liver Transpl Surg. 4(5 Suppl 1):1998;S9-S17.
85. Saldeen K., Friman S., Olausson M., Olsson R. Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis. Scand J Gastroenterol. 34(5):1999;535-540.
86. Gross C.R., Malinchoc M., Kim W.R., Evans R.W., Wiesner R.H., Petz J.L. et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology. 29(2):1999;356-364.
87. Graziadei I.W., Wiesner R.H., Marotta P.J., Porayko M.K., Hay J.E., Charlton M.R.et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology. 30(5):1999;1121-1127.
88. Goss J.A., Shackleton C.R., Farmer D.G., Arnaout W.S., Seu P., Markowitz J.S.et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg. 225(5):1997;472-481. discussion 481-3.
89. Narumi S., Roberts J.P., Emond J.C., Lake J., Ascher N.L. Liver transplantation for sclerosing cholangitis. Hepatology. 22(2):1995;451-457.
90. Nashan B., Schlitt H.J., Tusch G., Oldhafer K.J., Ringe B., Wagner S.et al. Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation. Hepatology. 23(5):1996;1105-1111.
91. Ricci P., Therneau T.M., Malinchoc M., Benson J.T., Petz J.L., Klintmalm G.B.et al. A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease. Hepatology. 25(3):1997;672-677.
92. Graziadei I.W., Wiesner R.H., Batts K.P., Marotta P.J., LaRusso N.F., Porayko M.K.et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology. 29(4):1999;1050-1056.
93. Vera A., Moledina S., Gunson B., Hubscher S., Mirza D., Olliff S.et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet. 360(9349):2002;1943-1944.
94. Dvorchik I., Subotin M., Demetris A.J., Fung J.J., Starzl T.E., Wieand S.et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology. 35(2):2002;380-384.
95. Stiehl A., Walker S., Stiehl L., Rudolph G., Hofmann W.J., Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol. 20(1):1994;57-64.
96. De Maria N., Colantoni A., Rosenbloom E., Van Thiel D.H. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology. 43(12):1996;1472-1479.